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The author replies: Pollack’s description of 
how his practice functions sounds like an exam-
ple of the patient-centered medical home and 
how it should operate. My patient, Mary, would 
have benefitted from a more comprehensive ap-
proach to her care in which everyone involved 
was providing excellent care in his or her realm 
of expertise. I agree that working harder will not 
fix broken systems. Health care providers and 
their staff will need to go through major learn-
ing processes that will take money, time, hard 
work, and dedication to make this transforma-
tion a success. We desperately need the Obama 
administration to support and fund the efforts to 
provide this type of care. One lingering concern 
that needs to be addressed is the potential con-
flict of interest between physicians’ payments 
and the care they provide to their patients. Even 
the perception that physicians have a financial 
disincentive to provide care will erode the pri-
macy of the patient–doctor relationship.
Greenberg rightly points out that primary 
care is a community that includes not only inter-
nists but also family physicians and pediatri-
cians. Each of these groups brings a different 
orientation to primary care, but all share a com-
mitment to taking full responsibility for the 
“care” of the patient. It is a community of care-
givers with whom I am proud to be identified. 
My story about Mary was not meant to be a com-
plaint about my career or to reinforce inaccurate 
stereotypes. It was first and foremost a story 
about Mary, a courageous woman for whom I 
had the privilege to care. It was also an attempt 
to articulate the joys, sorrows, challenges, and 
ultimately the deep satisfaction that come from 
this type of work. My hope is that it might in-
spire and attract medical students to this im-
mensely rewarding profession.
Diane R. Fingold, M.D.
Massachusetts General Hospital 
Boston, MA
Since publication of her article, the author reports no further 
potential conflict of interest.
Ovarian Toxicity from Sirolimus
To the Editor: Sirolimus prevents rejection of 
renal allografts by blocking the mammalian 
target of rapamycin (mTOR), a signaling path-
way known to regulate ovarian function.1 Siroli-
mus is being assessed as a treatment for autoso-
mal dominant polycystic kidney disease (ADPKD). 
Observational data suggest a potential for ovar-
ian toxicity, but this issue has not been evaluated 
in randomized, controlled trials.2
In the Suisse ADPKD study (ClinicalTrials.gov 
number, NCT00346918), a randomized, controlled 
trial conducted at the University Hospital Zurich 
from March 2006 through March 2010, we re-
viewed the occurrence of menstrual-cycle distur-
bances and the appearance of ovarian cysts3 in 
39 women with ADPKD, an inherited kidney dis-
ease that is not known to affect ovarian mor-
phology and function.4,5 The trial was conducted 
in accordance with the principles of the Declara-
tion of Helsinki, the Good Clinical Practice 
guidelines of the International Conference on 
Harmonization, and local regulatory require-
ments. The local medical ethics committee ap-
proved the trial protocol. All patients provided 
written informed consent. A total of 21 women 
received sirolimus, and 18 received standard care 
for 18 months. Abdominal magnetic resonance 
imaging was performed in each patient every 
6 months, and ovarian cysts larger than 2 cm in 
diameter were identified. Oligoamenorrhea was 
defined as no menstrual period for 3 months or 
more, or an interval of more than 35 days be-
tween menstrual periods. Analyses of prevalence 
were carried out with the use of exact logistic 
regression.
Wyeth (now Pfizer) provided the sirolimus 
but had no role in the trial design or in the col-
lection, analysis, or interpretation of the data or 
the writing of the manuscript. The authors had 
full access to the study data and take responsi-
bility for the integrity of the data, the accuracy 
of the data analysis, and the fidelity of this re-
port to the trial protocol.
Among patients who received sirolimus at a 
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dose of 1.5 mg per day, 11 of 21 with ADPKD 
(52%) reported menstrual-cycle abnormalities, 
as compared with 3 of 18 in the ADPKD control 
group (17%) (Table 1) (odds ratio, 5.3; 95% con-
fidence interval [CI], 1.0 to 37.0). Five patients in 
the sirolimus group, as compared with only 1 pa-
tient in the control group, reported more than 
one episode of oligoamenorrhea. Ovarian cysts 
were detected in 12 of 21 patients in the siroli-
mus group (57%), as compared with 5 of 18 in 
the control group (28%) (odds ratio, 3.4; 95% CI, 
0.8 to 17.0) (Table 1). At more than one visit after 
randomization, ovarian cysts were detected in 
6 patients in the sirolimus group, as compared 
with 2 in the control group. Differences in cycle 
disturbances were apparent in patients who were 
not receiving oral contraceptives; these differ-
ences were detected in 8 of 11 patients in the 
sirolimus group and in 2 of 9 in the control 
group. However, these differences were less ap-
parent in patients receiving oral contraceptives 
(3 of 10 in the sirolimus group and 1 of 9 in the 
control group). Differences between the siroli-
mus and control groups with respect to the pres-
ence of ovarian cysts did not appear to depend 
on the contraceptive method. Ovarian cysts were 
detected in 7 of 11 patients who used barrier 
methods in the sirolimus group and in 3 of 9 who 
Table 1. Characteristics of the Patients at Randomization and Oligoamenorrhea and Ovarian Cysts over Time.*
Variable
Sirolimus
(N = 21)
Control
(N = 18)
Characteristic at randomization
Age — yr 31±8 32±7
Body-mass index† 22±3 22±3
Estimated GFR — ml/min/1.73 m2‡  88±20  96±16
Menarche — yr§ 13±2 13±2
Parity — no. (%)§
Nulliparous 13 (62) 14 (78)
≥1 child 8 (38) 4 (22)
Contraception — no. (%)§
Hormonal 10 (48) 9 (50)
Barrier method 11 (52) 9 (50)
Oligoamenorrhea no./total no. (%)¶
Enrollment 3/21 (14) 2/17 (12) 
Randomization 2/20 (10) 1/15 (7) 
6 mo 9/21 (43) 2/18 (11)
12 mo 5/20 (25) 2/18 (11)
18 mo 5/19 (26) 1/18 (6)
Any visit after randomization 11/21 (52) 3/18 (17)
Ovarian cysts — no./total no. (%)
Enrollment 4/21 (19) 4/16 (25) 
Randomization 2/21 (10) 4/17 (24) 
6 mo 6/21 (29) 2/14 (14) 
12 mo 6/20 (30) 3/17 (18) 
18 mo 7/18 (39) 2/17 (12) 
Any visit after randomization 12/21 (57) 5/18 (28)
* Plus–minus values are means ±SD. GFR denotes glomerular filtration rate.
† The body-mass index is the weight in kilograms divided by the square of the height in meters.
‡ The GFR was estimated with the use of the Chronic Kidney Disease Epidemiology Collaboration equation.
§ Listed are data from patients’ self-reported medical histories at randomization.
¶ Listed are patients’ self-reported events during the 6 months before the visit.
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used barrier methods in the control group; they 
were detected in 5 of 10 patients who used oral 
contraceptives in the sirolimus group and in 2 of 
9 who used oral contraceptives in the control 
group).
Low-dose oral sirolimus appears to increase 
the risk of menstrual-cycle disturbances and 
ovarian cysts. Monitoring of sirolimus-associated 
ovarian toxicity is warranted and might guide 
clinical practice with the use of mTOR inhibitors.
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Pregnancy in a Woman with a Leptin-Receptor Mutation
To the Editor: Leptin is considered to have an 
important role in reproductive functions, includ-
ing menstrual-cycle regulation, pregnancy, and 
lactation.1,2 The absence of leptin action caused 
by functional mutations in the leptin gene (LEP) 
or the leptin receptor gene (LEPR) has been linked 
to infertility in rodents and humans.3-5 We report 
a pregnancy in a woman despite absent leptin 
signaling.
In 1998, we reported the case of a morbidly 
obese patient with a rare homozygous LEPR mu-
tation, which was shared by several affected 
siblings.4 The mutation was found in the pa-
tient’s blood and adipose tissue, indicating no 
evidence of chimerism. She had been followed 
for morbid obesity since early childhood, with 
abnormal compulsive-feeding behaviors and re-
duced levels of growth hormone and thyrotro-
pin.4 She entered puberty late, with irregular 
cycles after the age of 17 years. Repeated evalu-
ations of sex-hormone levels were considered to 
be normal after the age of 18 years. The patient 
underwent abdominoplasty at the age of 16 years 
and gastric-bypass surgery at the age of 24 years. 
Six months after gastric bypass, her weight had 
decreased from 220 kg (485 lb) to 170 kg (375 
lb), with a concurrent decrease in the body-mass 
index (the weight in kilograms divided by the 
square of the height in meters) from 81 to 62. 
She was counseled regarding contraception and 
was prescribed oral contraceptives. Two years 
after gastric bypass, just before an unplanned 
pregnancy, she had no diabetes, hypertension, 
respiratory disorders, or other recognized com-
plications of obesity.
Ultrasonographic examinations during preg-
nancy were considered normal except for sus-
pected macrosomia in the third trimester. The 
patient’s total weight gain during pregnancy was 
50 kg (110 lb) from a prepregnancy weight of 
180 kg (397 lb). Routine screening for gesta-
tional diabetes was normal. Although occasional 
elevated blood sugar levels were documented 
during the pregnancy, the glycated hemoglobin 
level in the third trimester was 5.6%. At 37 
weeks 5 days of gestation (on the basis of first-
trimester ultrasonography), the patient delivered 
a son by elective cesarean section, which was 
performed because of breech presentation and 
suspected macrosomia under epidural anesthe-
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